



## News Release

### **Puma Biotechnology Closes \$218 Million Public Offering of Common Stock**

**LOS ANGELES, Calif., Jan. 27, 2015** – Puma Biotechnology, Inc. (NYSE: PBYI), a development stage biopharmaceutical company, announced the closing of an underwritten registered public offering of 1,150,000 shares of its common stock at a price to the public of \$190.00 per share. The shares of common stock issued in the offering included 150,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares. The net proceeds from the offering were approximately \$205 million, after deducting the underwriting discount and estimated offering expenses payable by the Company.

BofA Merrill Lynch and J.P. Morgan acted as lead book-running managers and Citigroup acted as joint book-running manager for the offering. Leerink Partners LLC and Cowen and Company, LLC acted as co-managers for the offering.

The offering was made pursuant to an automatically effective shelf registration statement filed with the Securities and Exchange Commission on January 20, 2015. A final prospectus supplement was filed with the Securities and Exchange Commission and forms a part of the effective registration statement. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may be obtained by contacting BofA Merrill Lynch, 222 Broadway, New York, NY 10038, Attn: Prospectus Department, email: [dg.prospectus\\_requests@baml.com](mailto:dg.prospectus_requests@baml.com); J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, New York 11717, Phone: (866) 803-9204; or Citigroup, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, phone (800) 831-9146.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.

#### **Contact:**

Alan Auerbach or Mariann Ohanesian, Puma Biotechnology, Inc., +1 424 248 6500

[info@pumabiotechnology.com](mailto:info@pumabiotechnology.com)

[ir@pumabiotechnology.com](mailto:ir@pumabiotechnology.com)

#####